More Related Content More from SebastianChandra3 More from SebastianChandra3 (10) 1. Eur Heart J, Volume 42, Issue 39, 14 October 2021, Pages 4013–4024, https://doi.org/10.1093/eurheartj/ehab390
The content of this slide may be subject to copyright: please see the slide notes for details.
Summary of optimal and alternative antithrombotic strategies in
patients with peripheral arterial disease. ...
Editor's Notes Summary of optimal and alternative antithrombotic strategies in patients with peripheral arterial disease. aIn the absence of any other vascular disease. bThe addition of clopidogrel on top of low-dose aspirin and rivaroxaban can be decided case by case, taking into consideration type and length of stent, disease severity, and bleeding risk. If clopidogrel is added, it should be limited to 1 month to limit bleeding complications.100cThere are no data for a head-to-head comparison between R + A vs. A + C strategies. The latter has been empirically implemented and recommended for endovascular therapy,1 while the R + A has been recently assessed in a randomized trial.80 Also, the R + A strategy can be prolonged beyond the post-revascularization period with benefits on MACE and MALE.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
